They stated that the effect concerned the impact of tested compounds on the expression of nuclear receptors (PPARα, PPARγ, PPARδ), gluconeogenic genes (Pkc1, G6pc), and sterol regulatory element-binding protein 1c (SREBP-1c), which translated into the overall improvement of the carbohydrate-lipid metabolism and thus a significant hepatic steatosis attenuation in obese insulin-resistant mice models. The gene discussed is PPARG; the disease is fatty liver disease.